Literature DB >> 10777585

Roles of thermal instability and proteolytic cleavage in regulation of activated thrombin-activable fibrinolysis inhibitor.

M B Boffa1, R Bell, W K Stevens, M E Nesheim.   

Abstract

We have used site-directed mutagenesis and a recombinant expression system for thrombin-activable fibrinolysis inhibitor (TAFI) in order to identify the thrombin cleavage site in activated TAFI (TAFIa) and to determine the relative contribution of proteolytic cleavage and thermal instability in regulation of TAFIa activity in clots. Arg-330 of TAFIa had been proposed to be the thrombin cleavage site based on studies with trypsin, but mutation of this residue to Gln did not prevent thrombin-mediated cleavage nor did mutation to Gln of the nearby Arg-320 residue. However, mutation of Arg-302 to Gln abolished thrombin-mediated cleavage of TAFIa. All TAFIa variants were susceptible to plasmin cleavage. Interestingly, all Arg to Gln substitutions decreased the thermal stability of TAFIa. The antifibrinolytic potential of the TAFI mutants in vitro correlates with the thermal stability of their respective TAFIa species, indicating that this property plays a key role in regulating the activity if TAFIa. Incubation of TAFIa under conditions that result in complete thermal inactivation of the enzyme accelerates subsequent thrombin- and plasmin-mediated cleavage of TAFIa. Moreover, the extent of cleavage of TAFIa by thrombin does not affect the rate of decay of TAFIa activity. Collectively, these studies point to a role for the thermal instability, but not for proteolytic cleavage, of TAFIa in regulation of its activity and, thus, of its antifibrinolytic potential. Finally, we propose a model for the thermal instability of TAFIa.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10777585     DOI: 10.1074/jbc.275.17.12868

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

1.  Thrombin activatable fibrinolysis inhibitor activation and bleeding in haemophilia A.

Authors:  J H Foley; M E Nesheim; G E Rivard; K E Brummel-Ziedins
Journal:  Haemophilia       Date:  2011-09-20       Impact factor: 4.287

2.  Thrombin-activable fibrinolysis inhibitor zymogen does not play a significant role in the attenuation of fibrinolysis.

Authors:  Jonathan H Foley; Paula Kim; Michael E Nesheim
Journal:  J Biol Chem       Date:  2008-02-05       Impact factor: 5.157

3.  Thrombin Activable Fibrinolysis Inhibitor in Beta Thalassemia.

Authors:  Aruna Chhikara; Sunita Sharma; Jagdish Chandra; Anita Nangia
Journal:  Indian J Pediatr       Date:  2016-08-03       Impact factor: 1.967

4.  Plasma carboxypeptidase B downregulates inflammatory responses in autoimmune arthritis.

Authors:  Jason J Song; Inyong Hwang; Kyung H Cho; Michael A Garcia; Arthur J Kim; Tiffany H Wang; Tamsin M Lindstrom; Annette T Lee; Toshihiko Nishimura; Lei Zhao; John Morser; Michael Nesheim; Stuart B Goodman; David M Lee; S Louis Bridges; Peter K Gregersen; Lawrence L Leung; William H Robinson
Journal:  J Clin Invest       Date:  2011-08-01       Impact factor: 14.808

5.  Flexibility of the thrombin-activatable fibrinolysis inhibitor pro-domain enables productive binding of protein substrates.

Authors:  Zuzana Valnickova; Laura Sanglas; Joan L Arolas; Steen V Petersen; Christine Schar; Daniel Otzen; Francesc X Aviles; F Xavier Gomis-Rüth; Jan J Enghild
Journal:  J Biol Chem       Date:  2010-09-29       Impact factor: 5.157

6.  The roles of selected arginine and lysine residues of TAFI (Pro-CPU) in its activation to TAFIa by the thrombin-thrombomodulin complex.

Authors:  Chengliang Wu; Paul Y Kim; Reg Manuel; Marian Seto; Marc Whitlow; Mariko Nagashima; John Morser; Ann Gils; Paul Declerck; Michael E Nesheim
Journal:  J Biol Chem       Date:  2008-12-12       Impact factor: 5.157

7.  The crystal structure of thrombin-activable fibrinolysis inhibitor (TAFI) provides the structural basis for its intrinsic activity and the short half-life of TAFIa.

Authors:  Kanchan Anand; Irantzu Pallares; Zuzana Valnickova; Trine Christensen; Josep Vendrell; K Ulrich Wendt; Herman A Schreuder; Jan J Enghild; Francesc X Avilés
Journal:  J Biol Chem       Date:  2008-07-31       Impact factor: 5.157

8.  The extended cleavage specificity of human thrombin.

Authors:  Maike Gallwitz; Mattias Enoksson; Michael Thorpe; Lars Hellman
Journal:  PLoS One       Date:  2012-02-27       Impact factor: 3.240

Review 9.  Thrombin Activatable Fibrinolysis Inhibitor (TAFI): An Updated Narrative Review.

Authors:  Machteld Sillen; Paul J Declerck
Journal:  Int J Mol Sci       Date:  2021-04-01       Impact factor: 5.923

10.  Biochemical characterization of bovine plasma thrombin-activatable fibrinolysis inhibitor (TAFI).

Authors:  Zuzana Valnickova; Morten Thaysen-Andersen; Peter Højrup; Trine Christensen; Kristian W Sanggaard; Torsten Kristensen; Jan J Enghild
Journal:  BMC Biochem       Date:  2009-05-05       Impact factor: 4.059

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.